Back to results
US 2026/0243783 A1Published application
Immunoassays for Buprenorphine and Metabolites
OwnerRajendra Singh, Soon Jin Oh +1inventors
InventorsRajendra Singh, Soon Jin Oh, Jie Liang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies that specifically bind to buprenorphine and its metabolites norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide analytes. Such antibodies can be used to detect a buprenorphine analyte in a sample, such as in a homogeneous enzyme immunoassay method. Hapten structures to elicit such antibodies and conjugates useful in immunoassays are also described.
Claims31
A compound of Formula 1:
- wherein:
- R1 is —Y—Z;
- and
- Y is a linking group selected from —(CH2)nCO—, —(CH2)nNHCO—, —(CH2)n—O—(CH2)n—CO—, —(CH2)n—CO—(CH2)nCO—, —(CH2)n—CO—(CH2)n—NHCO—, and —(CH2)n—S—(CH2)n—CO—;
- Z is selected from hydrogen, OH, SH, S-acyl, O-alkyl, halogen, NH2, epoxy, maleimidyl, haloacetamide, carboxyl, activated carboxyl, an alkyne, an azide, an immunogenic carrier, a protein, and a label;
- and
- R2 is H, glucuronic acid, glucuronide salt, or a protecting group,
- and salts thereof.
5 more elements
A compound of the Formula 2:
- R1 is selected from H, -cyclopropyl methyl, and Y—Z;
- R3 is selected from OH, NH2, NHR4, and Y—Z—R4
- Y is a linking group selected from —(CH2)nCO—, —(CH2)nNHCO—, —(CH2)n—O—(CH2)n—CO—, —(CH2)n—CO—(CH2)nCO—, —(CH2)n—CO—(CH2)n—NHCO—, and —(CH2)n—S—(CH2)n—CO—;
- Z is selected from hydrogen, OH, SH, S-acyl, O-alkyl, halogen, NH2, epoxy, maleimidyl, haloacetamide, carboxyl, activated carboxyl, an alkyne, an azide, an immunogenic carrier, a protein, and a label;
- and
- R4 is selected from an immunogenic carrier, a protein, an enzyme, and a label,
- and salts thereof.
4 more elements
(canceled)
An antibody that specifically binds to the compounds of Formula 1 or Formula 2, wherein the antibody comprises:
- a variable heavy chain (VH) polypeptide comprising:
- a VH CDR1 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 1-23,
- a VH CDR2 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 24-46, and
- a VH CDR3 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 47-69;
- and
- a variable light chain (VL) polypeptide comprising:
- a VL CDR1 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 70-92, and
- a VL CDR2 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 93-115, and
- a VL CDR3 comprising the amino acid sequence selected from any one of SEQ ID NOs:
- 116-138.
12 more elements
Dependencies are inferred from the claim text.